Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy
| Autor: | Peter Wipfler, Wolfgang Hitzl, Eugen Trinka, Jörg Kraus, Julia Feige, Janne Cadamuro, Georg Pilz, Christian Puttinger, Hannes Oberkofler, Ciara O’Sullivan, Elisabeth Haschke-Becher, Tobias Moser, Andrea Harrer |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
QH301-705.5
Medicine (miscellaneous) immunization medicine.disease_cause Rubella Article General Biochemistry Genetics and Molecular Biology medicine infections Biology (General) Cladribine antibody levels Tetanus business.industry Diphtheria Varicella zoster virus Antibody titer virus diseases lymphodepletion immune reconstitution Hepatitis B vaccination medicine.disease Immunization Immunology titers business medicine.drug |
| Zdroj: | Biomedicines Biomedicines, Vol 9, Iss 1584, p 1584 (2021) Volume 9 Issue 11 |
| ISSN: | 2227-9059 |
| DOI: | 10.3390/biomedicines9111584 |
| Popis: | Cladribine (CLAD) is a lymphodepleting agent approved for active relapsing multiple sclerosis (MS). The impact of CLAD on the adaptive humoral immune system has not sufficiently been studied. This study aimed to assess the influence of CLAD treatment on specific antibody titers to common pathogens. We included 18 MS patients treated with CLAD. Serum IgG antibody levels to measles, mumps, rubella, hepatitis B and varicella zoster virus (VZV), as well as diphtheria and tetanus toxins, were measured prior to the initiation of treatment and at 12 and 24 months after first CLAD administration. Moreover, specimens were longitudinally analyzed regarding absolute blood concentrations of IgG and main lymphocyte subsets. No reduction in antibody levels against measles, mumps, rubella, VZV, hepatitis B, diphtheria toxin and tetanus toxin associated with CLAD treatment was observed. Loss of seroprotection occurred in < 1%. We found no significant impact of CLAD on absolute serum IgG levels. Absolute lymphocyte counts were significantly reduced at the end of each treatment year (p < 0.00001 and p < 0.000001). This study suggests that CLAD does not interfere with the pre-existing humoral immunologic memory in terms of pathogen-specific antibody titers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|